Biogen Inc. Files 8-K on Shareholder Votes and Financials

Ticker: BIIB · Form: 8-K · Filed: 2025-06-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, financial-reporting, sec-filing

Related Tickers: BIIB

TL;DR

Biogen filed an 8-K on June 23rd about shareholder votes and financials from June 17th.

AI Summary

Biogen Inc. filed an 8-K on June 23, 2025, reporting on events that occurred on June 17, 2025. The filing primarily concerns the submission of matters to a vote of security holders and includes financial statements and exhibits. Biogen Inc. is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This filing provides updates on important corporate actions and financial reporting for Biogen Inc., which can influence investor decisions.

Risk Assessment

Risk Level: low — This is a routine filing for corporate actions and financial reporting, not indicating immediate operational or financial distress.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Biogen Inc.'s security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the significance of the 'Financial Statements and Exhibits' mentioned in the filing?

This indicates that the filing includes important financial information and supporting documents for Biogen Inc., which are crucial for investors to assess the company's performance.

When did Biogen Inc. change its name from Biogen Idec Inc.?

Biogen Inc. changed its name from Biogen Idec Inc. on April 27, 2007.

What is Biogen Inc.'s fiscal year end?

Biogen Inc.'s fiscal year ends on December 31.

What is the SIC code for Biogen Inc.?

The Standard Industrial Classification (SIC) code for Biogen Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0000875045-25-000023.txt : 20250623 0000875045-25-000023.hdr.sgml : 20250623 20250623161857 ACCESSION NUMBER: 0000875045-25-000023 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250617 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250623 DATE AS OF CHANGE: 20250623 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 251065181 BUSINESS ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 225 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC. DATE OF NAME CHANGE: 20070427 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 biib-20250617.htm 8-K biib-20250617 0000875045 false 0000875045 2025-06-17 2025-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Biogen Inc. (Exact name of registrant as specified in its charter) Delaware 0-19311 33-0112644 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 225 Binney Street , Cambridge , Massachusetts 02142 (Address of principal executive offices; Zip Code)      Registrant’s telephone number, including area code: ( 617 ) 679-2000 Not Applicable (Former name or former address, if changed since last report.)      Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07     Submission of Matters to a Vote of Security Holders. On June 17, 2025, Biogen Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the Annual Meeting are as follows: 1. Stockholders elected eleven nominees to the Board of Directors to serve for a one-year term extending until the 2026 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Caroline

View on Read The Filing